Coronary disease & ACSSecondary analysis

Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome

CirculationPublished

  • Secondary analysis of the ODYSSEY OUTCOMES randomised trial
  • prespecified analysis

Authors' conclusion

In statin-treated patients with recent acute coronary syndrome, risk of PAD events is related to lipoprotein(a) level and is reduced by alirocumab, particularly among those with high lipoprotein(a).

Study context

Population
Patients with recent ACS on intensive or maximum-tolerated statin treatment
Participants
18,924 patients
Comparison
Alirocumab vs placebo
Primary endpoint
PAD events (critical limb ischemia, limb revascularization, or amputation for ischemia) and VTE (DVT or PE)

Primary result

As reported in the abstract

Alirocumab vs PlaceboHazard ratio (95% CI)P value
PAD events
0.69(0.54–0.89)
P = 0.004
VTE
0.67(0.44–1.01)
P = 0.06
Peripheral artery disease (PAD) events (all patients)
246
Venous thromboembolism (VTE) (all patients)
92

Further findings

Lipoprotein(a) and LDL-Ccorrected reduction with alirocumab

Median relative reduction in lipoprotein(a)
23.5%
Median relative reduction in LDL-Ccorrected
70.6%
  • baseline medians 21 and 75 mg/dL

Placebo: risk by baseline quartile

PAD events by lipoprotein(a) quartile
P for trend = 0.0021
PAD events by LDL-Ccorrected quartile
P for trend = 0.06
VTE by lipoprotein(a) quartile
P for trend = 0.06
VTE by LDL-Ccorrected quartile
P for trend = 0.85

Reduction in PAD events with alirocumab by baseline quartile

By lipoprotein(a) quartile
P for trend = 0.03
By LDL-Ccorrected quartile
P for trend = 0.50

Change to Month 4 and VTE risk (alirocumab)

Change in lipoprotein(a), but not LDL-Ccorrected, associated with risk of VTE and of VTE + PAD events

Original publication

Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. Circulation. Published 29 March 2020. doi:10.1161/circulationaha.120.046524

Summarised from the published abstract; every number is checked against it